Board Appointment

Belluscura

12/09/2025 16:57

RNS Number : 2098Z

Belluscura PLC

12 September 2025

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Belluscura plc

("Belluscura" or the "Company" or "Group")

 

Board Appointment

 

Belluscura has appointed Guy Peters as non executive director

 

LONDON, U.K. and PLANO, TX, U.S. (12 September 2025). Belluscura plc (AIM:BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that Guy Peters has joined the Board as a non-executive director with immediate effect.

Guy is a qualified solicitor who moved into merchant and investment banking early in his career. He has over 30 years' experience working with small to medium sized businesses across a broad variety of sectors as a board member or as an external corporate financier, stockbroking advisor, solicitor or consultant. His expertise encompasses operational, business development, legal and accounting matters as well as IPOs, fundraisings, acquisitions, mergers and disposals. 

In recent months Guy has been assisting, Omaha Value, Inc. ("Omaha"), a private US-based merchant banking and investment group which had made a funding proposal to the Company, as set out in the Company's notification of 30 June 2025,

The Company announced on 11 August 2025 that it had terminated its agreement with Omaha, and that it had proceeded to sign a non-binding letter of intent with another US company for that company to acquire certain assets and liabilities of Belluscura LLC, the Company's wholly-owned US subsidiary. The potential acquiror was granted an exclusivity period to complete its due diligence. This period of exclusivity has now expired, and no definitive agreement has been signed.

With the expiry of the aforementioned exclusivity period, the Company has been approached once more by Omaha to consider a revised funding proposal from Omaha and a connected company called AI Ventures, Inc, (together the "Omaha Investor Group") with a proposal to refinance the Company. The Company, with Guy's assistance, is continuing to evaluate a range of options to substantially strengthen Belluscura's capital position, supporting both the Company's short-term cash requirements and its significant medium-term growth prospects.  Any agreement with Omaha will involve Guy receiving a share of the fees and other rewards due to Omaha, details of which will be notified as part of any requisite shareholders' approval process and subject to any necessary consents to be obtained at the time.

While the Board can confirm that discussions regarding the Fundraising are proceeding as set out above, there can be no certainty that the Fundraising will be completed.  If the Fundraising does not proceed as set out above in the next few days the Company will be unable to meet its immediate cash requirements. 

The ongoing funding discussions means that the Company is still not yet able to finalise the 2024 Annual Report and Accounts and as a result trading in the Company's shares on AIM remains suspended.

AIM Rules Schedule 2(g) disclosures

Pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies, Guy Richard Peters is, or has during the last five years, been a director or partner of the following companies and partnerships:

Current Directorships or Partnerships
Previous Directorships or Partnerships
Triple O Corporate Services Limited
Accounting Value Solutions Limited
D.E.S Properties Limited
Hydrogen Utopia International PLC
HU2021 International UK Limited


 

Guy Peters was appointed a director and CEO of Hume Capital Securities PLC on 23 June 2014 and resigned on 16 March 2015. Guy resigned following the appointment of a special administrator. Guy agreed to become a director and CEO on the basis that a refinancing seemed very likely at the time. Ultimately, the Financial Conduct Authority ("FCA") decided that a refinancing was unlikely to work and suggested to the then Chairman that the Board should put Hume Capital Securities PLC into special administration to protect clients' assets. Hume Capital Securities was put into special administration on 16 March 2015. Whilst the Special Administration is yet to complete, the loss to creditors is not expected to be more than £1.75m.

Hume Capital Securities PLC was named XCap Securities PLC between 27 July 2010 - 5 February 2014. On 31 May 2013, the FCA imposed a financial penalty of £120,900 on XCap Securities PLC for breaches of certain rules regarding protection of client money and client assets. The actual breaches occurred between 29 June 2010 and 31 August 2011. Both the breaches and the imposition of the fine occurred before Guy Peters was employed by XCap Securities PLC and more than a year before he became a director and CEO of Hume Capital Securities PLC.

 

Guy holds no shares in Belluscura. There are no other disclosures under AIM Rules Schedule 2(g).

 

 

For further information please contact:

 

 

Belluscura plc
Tel: +44 (0)20 3128 8100
Paul Tuson, Chairman
Robert Rauker, Chief Executive Officer
SPARK Advisory Partners Limited - Nominated Adviser
Tel: +44 (0)20 3368 3550
Neil Baldwin / Dillon Wall
Dowgate Capital Limited - Joint Broker
Tel: +44 (0)20 3903 7715
Russell Cook / Daniel Ingram
Allenby Capital Limited - Joint Broker
Tel: +44 (0)20 3328 5656
Guy McDougall / Amrit Nahal (Sales and Corporate Broking)
Jeremy Porter / Lauren Wright (Corporate Finance)
MHP - Financial PR & Investor Relations
Tel: +44 (0)20 3128 8100
Katie Hunt / Matthew Taylor
email: Belluscura@mhpgroup.com

 

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
BOAUUVVRVUUKAAR